JTWM
NBIX icon

Jackson Thornton Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Jackson Thornton Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$420K Sell
3,260
-248
-7% -$32.9K 0.04% 128
2025
Q4 		$482K Buy
3,508
+137
+4% +$19.8K 0.05% 116
2025
Q3 		$469K Buy
+3,371
New +$457K 0.05% 107

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jackson Thornton Wealth Management's NBIX Position: Q1 2026 in Review

Jackson Thornton Wealth Management reduced its Neurocrine Biosciences (NBIX) stake by 7.1% in Q1 2026, selling an estimated $32.9K and leaving 3,260 shares worth $420K. The position accounts for 0.04% of the portfolio, ranked #128.

Jackson Thornton Wealth Management first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $482K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Jackson Thornton Wealth Management held 3,260 shares of Neurocrine Biosciences worth $420K as of Q1 2026.
  • Jackson Thornton Wealth Management sold 248 Neurocrine Biosciences shares in Q1 2026, an estimated $32.9K.
  • Neurocrine Biosciences made up 0.04% of Jackson Thornton Wealth Management's portfolio in Q1 2026, its #128 holding.
  • Jackson Thornton Wealth Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Jackson Thornton Wealth Management's Neurocrine Biosciences position peaked at $482K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.